The European Commission Has Approved 20-mg Tablets of Rimonabant Acomplia
Sanofi-Aventis has high hopes for obesity drug Rimonabant Acomplia, launched in Britain this week, but its rollout across the EU is hard to predict given the politics of access to new drugs in Europe. Patients presenting with abdominal obesity who also have diabetes and/or dyslipidemia are most likely to benefit from rimonabant therapy. Almost 50% of adults with a large waist circumference (102 cm/40 inches in men, 88 cm/35 inches in women) also have at least 3 additional cardiometabolic risk factors. Rimonabant Acomplia (new weight loss miracle pill) is the first in a new class of drugs called cannabinoid subtype 1 (CB1) blockers, which work by selectively blocking receptors in the brain and peripheral organs that play a key role in glucose and lipid metabolism (eg, adipose tissue, the liver, gastrointestinal tract, and muscle). CB1 receptor blockade serves to decrease hyperactivity of the endocannabinoid system, which has been recently characterized as playing an important role in regulating body weight, controlling energy balance, and glucose and lipid metabolism. Sanofi has priced Rimonabant Acomplia at $100 dollars (55.20 pounds,or more cheap) for one month’s supply in Britain, which equates to $3.14 per tablet (2.50 euros),that if you buy brand pills.Of corse you can chose Generic version ofRimonabant Acomplia that is more cheap. Expected to sell for 20% more in the U.S. That is a somewhat lower price than analysts had expected for the drug, which is viewed as Sanofi’s most important new product, with potential annual sales worldwide of more than $3 billion. Sanofi hopes to start selling it in the U.S. before the year-end.
Acomplia Rimonabant was approved for use in Europe, along with diet and exercise, in treating obese patients, or overweight people who also have diabetes or high cholesterol.
